Oncology Center of Excellence (OCE)
Transcript of Oncology Center of Excellence (OCE)
![Page 1: Oncology Center of Excellence (OCE)](https://reader031.fdocuments.in/reader031/viewer/2022012916/61c6a3ec60e7225bf22541b4/html5/thumbnails/1.jpg)
Oncology Center of Excellence (OCE)
Jessica Boehmer, MBARegulatory Scientist
Office of Hematology and Oncology Products (OHOP)
![Page 2: Oncology Center of Excellence (OCE)](https://reader031.fdocuments.in/reader031/viewer/2022012916/61c6a3ec60e7225bf22541b4/html5/thumbnails/2.jpg)
2
• What is Expanded Access (EA)?• Current Process for Oncology EA Requests• Project Facilitate
– Process
– Benefits
Overview
![Page 3: Oncology Center of Excellence (OCE)](https://reader031.fdocuments.in/reader031/viewer/2022012916/61c6a3ec60e7225bf22541b4/html5/thumbnails/3.jpg)
3
What is Expanded Access?
![Page 4: Oncology Center of Excellence (OCE)](https://reader031.fdocuments.in/reader031/viewer/2022012916/61c6a3ec60e7225bf22541b4/html5/thumbnails/4.jpg)
4
Current Process for Oncology EA Requests
![Page 5: Oncology Center of Excellence (OCE)](https://reader031.fdocuments.in/reader031/viewer/2022012916/61c6a3ec60e7225bf22541b4/html5/thumbnails/5.jpg)
5
Current Process
• EA requests may be received by:– FDA/CDER’s Division of Drug Information (DDI) or
– by the review Division
• Requests arrive via phone, email, fax, or mail.
![Page 6: Oncology Center of Excellence (OCE)](https://reader031.fdocuments.in/reader031/viewer/2022012916/61c6a3ec60e7225bf22541b4/html5/thumbnails/6.jpg)
6
Current Process• If received by DDI, they collect:
– Physician/requestor name
– Patient initials
– Drug/Biologic
– Drug/Biologic manufacturer
– Can IRB approval occur prior to treatment?
• DDI forwards to review Division
![Page 7: Oncology Center of Excellence (OCE)](https://reader031.fdocuments.in/reader031/viewer/2022012916/61c6a3ec60e7225bf22541b4/html5/thumbnails/7.jpg)
7
Current Process
• Review Division contacts requestor to request: Signed/completed Form FDA 3926 CV or physician qualifications Letter of Authorization (LOA)
• Review Division reviews complete request upon receipt• Review Division informs requestor if they may proceed
with treatment
![Page 8: Oncology Center of Excellence (OCE)](https://reader031.fdocuments.in/reader031/viewer/2022012916/61c6a3ec60e7225bf22541b4/html5/thumbnails/8.jpg)
8
Planned Process for Project Facilitate
![Page 9: Oncology Center of Excellence (OCE)](https://reader031.fdocuments.in/reader031/viewer/2022012916/61c6a3ec60e7225bf22541b4/html5/thumbnails/9.jpg)
9
Project Facilitate - Process• Single point of contact for all oncology EA requests• Patient calls will continue to be supported by DDI staff• Project Facilitate staff will navigate requestor thru SPI
request process, provide:– IRB resource options– Pharma/biotech contact– Advice on other necessary information (e.g. CV, protocol,
patient history) to complete their request– Assistance completing form FDA 3926, if needed
![Page 10: Oncology Center of Excellence (OCE)](https://reader031.fdocuments.in/reader031/viewer/2022012916/61c6a3ec60e7225bf22541b4/html5/thumbnails/10.jpg)
10
Project Facilitate – Process• Requestor contacts drug manufacturer to
secure Letter of Authorization (LOA) and cc’s Project Facilitate
• If provided, Project Facilitate forwards complete request to appropriate Division
• If not provided, Project Facilitate documents reason, if available (e.g. lack of supply)
![Page 11: Oncology Center of Excellence (OCE)](https://reader031.fdocuments.in/reader031/viewer/2022012916/61c6a3ec60e7225bf22541b4/html5/thumbnails/11.jpg)
11
Project Facilitate - Benefits
![Page 12: Oncology Center of Excellence (OCE)](https://reader031.fdocuments.in/reader031/viewer/2022012916/61c6a3ec60e7225bf22541b4/html5/thumbnails/12.jpg)
12
Project Facilitate - Benefits
• Streamline submission: one point of contact for all oncology EA requests (CDER & CBER products)
• Dedicated staff with central, formalized training available during business hours to support requestors via phone or email– First phase: staffed by a Lead Regulatory Project Manager, and
Regulatory Project Managers from Review Divisions, assigned on rotation
– Permanent staff may be implemented after assessment of initial phase
![Page 13: Oncology Center of Excellence (OCE)](https://reader031.fdocuments.in/reader031/viewer/2022012916/61c6a3ec60e7225bf22541b4/html5/thumbnails/13.jpg)
13
Project Facilitate - Benefits
• Step-by-step support in completing request• Collection of metrics on if access to drug
provided by drug manufacturer, and if not, why?
• Follow up / reminders
![Page 14: Oncology Center of Excellence (OCE)](https://reader031.fdocuments.in/reader031/viewer/2022012916/61c6a3ec60e7225bf22541b4/html5/thumbnails/14.jpg)
14
Acknowledgements
Richard PazdurTamy KimNatasha KormanikMichael MenefeeAlice KacubaRea BlakeyKirsten GoldbergPaul KluetzGideon BlumenthalMarc TheoretSean KhozinKeagan LenihanCatherine ChewKyle Thomson
Megan LarkinAndrea Furia-HelmsSamir ShaikhAllison HoffmanJanice KimKe LiuLori TullWilson BryanKarla WatersPam BalcazarMara MillerElleni AlebachewWanda NguyenPatricia Garvey
Rebecca CohenTheresa CariotiMichael GwathmeyKristopher KolibabLaura WallKimberly ScottEsther ParkBeatrice KallungalSuria YesminKristin JarrellDianne SpillmanSherwin SapasapTony CossentinoTawanna Stokes
Beatrice KallungalMitchell ChanJana HighsmithMichael PhillipsMonica HughesJēnna ReesePauline Hittle